Express Scripts' Three-Year Drug Trend Forecast Projects That Three of the Four Costliest Therapy Classes Will Be Specialty Conditions ST. LOUIS, May...
Study Shows Effects of Treatment with ABILIFY MAINTENA™ (Aripiprazole) on Psychiatric Hospitalization Rates for Patients with Schizophrenia...
Vortioxetine, a new multimodal agent in development for the treatment of major depression, shows effects on cognitive function in several preclinical...
Over the past two years, two studies showed the Niaspan cholesterol drug did not benefit patients. Yet AbbVie has managed to maintain revenue...
And so another busy day comes to a close. Since we were occupied with sundry tasks late this afternoon, we thought you may appreciate getting caught up with a few headlines that passed under our nose. Thanks for stopping by today and we hope you have a pleasant evening...
FDA Panel Backs New Version Of Genzyme Drug (Yahoo/AP)
FDA Extends Review Of Pfizer Osteoporosis Drug (Reuters)
Sandoz Loses Bid To Sell Generic Biaxin (Bloomberg News)
1 Comment
Concerning the New Version of Genzyme:
"The FDA decided the new version would have to be evaluated as a separate product because of major differences in the manufacturing process."
As it should be.
G'night to you, Ed.